Through genome-wide DNA methylation and transcriptomic analysis in trastuzumab-sensitive (SK) and trastuzumab-resistant (SKTR) BC cell lines, the research singled out the TGFBI gene with the highest hypermethylation-associated silencing both at the transcriptional and protein level. Here, TGFBI is linked to breast cancer.